Kevin Lynch

Medicine · Health Sciences

5h-index199citations31works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(19), Monoclonal and Polyclonal Antibodies Research(14), CAR-T cell therapy research(12), Cancer Cells and Metastasis(4), Nitric Oxide and Endothelin Effects(3)

Publications31 total

Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024Open Access
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
Cancer Research·2024· 16 citedOpen Access
Data from Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon Cancer
2023Open Access
Data from Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon Cancer
2023· 1 citedOpen Access
Supplementary Data from Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon Cancer
2023Open Access
Supplementary Data from Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon Cancer
2023Open Access
1444 Targeting sialic acid on stromal cells reverses T cell suppression in the colorectal tumour microenvironment a new tumour stromal cell immune checkpoint
Regular and Young Investigator Award Abstracts·2022Open Access
ATG-101, a tetravalent PD-L1×4-1BB bispecific antibody, augments anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation
Research Square (Research Square)·2022Open Access
ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
Annals of Surgical Oncology·2022· 1 cited
page 1 of 2Next →

Frequent Co-authors

Jay Mei(16), Hui Yuwen(14), Huajing Wang(14), Tengteng Li(14), Bohua Li(14), David Flowers(14), Marc Presler(14), Kalyanasundaram Subramanian(14), Bing Hou(14), Yijing Ren(13), Yun-kai Zhang(13), Peng Chen(13), Ao Sun(13), Gang Bian(13), Jia Xue(13), Jingjing Wang(13), Xiaowen He(13), Bo Shan(13), Oliver Treacy(5), Niamh Leonard(5)